glipizide has been researched along with glucagon-like peptide 1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drucker, DJ; Goldberg, RB; Holman, R | 1 |
| Eiermann, GJ; Feng, Y; Howard, AD; Li, C; Li, Z; Mu, J; Petrov, A; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Chamarthi, B; Chen, L; Florez, JC; Goldfine, A; Hudson, M; Kaur, V; Littleton, KR; Manning, AK; Merino, J; Srinivasan, S; Thomas, MK | 1 |
| Dorsey-Trevino, EG; Florez, JC; Kaur, V; Leong, A; Mercader, JM | 1 |
| Han, X; Ji, L; Li, J; Li, Y; Qiu, L; Ren, H; Shi, Z; Wu, K; Yang, F; Zhang, X; Zhao, C; Zhong, H; Zhou, X | 1 |
| Heinla, K; Johannson, A; Katus, U; Rünkorg, K; Toompere, K; Uusküla, A; Volke, V | 1 |
1 review(s) available for glipizide and glucagon-like peptide 1
| Article | Year |
|---|---|
Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glipizide; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
1 trial(s) available for glipizide and glucagon-like peptide 1
| Article | Year |
|---|---|
Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial.
Topics: Acarbose; Blood Glucose; China; Diabetes Mellitus, Type 2; Ecosystem; Gastrointestinal Microbiome; Gastrointestinal Tract; Glipizide; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Research; Vildagliptin | 2022 |
4 other study(ies) available for glipizide and glucagon-like peptide 1
| Article | Year |
|---|---|
Clinical decisions. Management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Glucagon-Like Peptide 1; Humans; Hypertension; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Obesity; Pioglitazone; Thiazolidinediones | 2008 |
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Ki-67 Antigen; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides | 2009 |
Topics: Adult; Aged; Alleles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotyping Techniques; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Metformin; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Transcription Factor 7-Like 2 Protein | 2018 |
Association of GLP1R Polymorphisms With the Incretin Response.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glipizide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Incretins; Insulin | 2022 |